Frontlight ResearchEarly access
Taking peoplePhase 3
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Key facts
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Where
- Japan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 180 people, planned
- Started
- 16 Sept 2025
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- EB-1020 (Centanafadine) low dose
- EB-1020 (Centanafadine) high dose
- Record updated
- 23 December 2025
Who can take part
- Age
- 6 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- <Rollover participants>
- Participants who completed the 6-week treatment period and 1-week follow-up period in the preceding double-blind parent trial and did not meet the criteria for discontinuation of the IMP at Week 6
- Participants who have not been found to have major problems with trial requirements, such as compliance with the IMP, in the preceding double-blind parent trial; <De novo participants>
- Participants with a primary diagnosis of ADHD based on DSM-5 diagnostic criteria, differentiated from other mental disorders using the MINI-KID, excluding other specified ADHD or unspecified ADHD
- Participants with a symptom total raw score of >= 28 on the ADHD-RS-5 at baseline
- Participants with a score of 4 or higher on the Clinical Global Impression Severity - ADHD (CGI-S-ADHD) at baseline
Who cannot take part
- Participants who plan to use prohibited medication during the trial. Participants who used prohibited medication during the preceding double-blind parent trial should be excluded if the investigator or subinvestigator judges that there is a possibility of repeated use of prohibited medication; <De novo participants>
- Participants with a diagnosis of major depressive disorder (MDD), based on the DSM-5 diagnostic criteria who currently have a major depressive episode, or who have required treatment for MDD within the past 3 months prior to screening. Also, participants who, in the judgment of the investigator or subinvestigator, may have a worsening of MDD during the trial or may require treatment during the trial period
- Participants who cannot agree to discontinuation of prohibited concomitant medication, such as ADHD medication or antidepressants
- Participants determined to have the following diseases based on an interview using the MINI-KID; Tourette's disorder; Panic disorder; Conduct disorder; Psychotic disorder; Post-traumatic stress disorder; Bipolar disorder
- Participants with a generalized anxiety disorder requiring pharmacotherapy, based on the DSM-5 diagnostic criteria
- Participants with an autism spectrum disorder based on the DSM-5 diagnostic criteria
- Participants with a personality disorder, oppositional defiant disorder, or obsessive-compulsive disorder that is the primary focus of treatment, based on the DSM-5 diagnostic criteria
- Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence; Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5 (over the last 6 months) on the section of suicidal ideation or a history of suicidal behavior (over the last 6 months) on the Baseline/Screening version of the C-SSRS at screening
- Participants with a diagnosis of substance use disorder
- Participants who have laboratory test results at screening as follows:; Platelets<=130,000/mm3; Hemoglobin<=11.2 g/dL; Neutrophils, absolute<=1000/mm3; AST > 2 x ULN; ALT > 2 x ULN; eGFR < 45 mL/min/1.73 m2, calculated by the CKiD U25 equation; CPK>=2 x ULN (except for the participants that the medical monitor determines that inclusion is possible based on discussion about their condition with the investigator or subinvestigator); Abnormal values for both free T4 and TSH
- <Rollover participants>
- Participants who have a positive pregnancy test result at baseline
- Participants who were found to have serious or severe adverse events that were judged to be related to the IMP in the preceding double-blind parent trial
- Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence; Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5 on the section of suicidal ideation or reported suicidal behavior on the since last visit version of the Columbia-Suicide Severity Rating Scale (C SSRS) in the preceding double-blind parent trial
- Participants who have a positive pregnancy test result at baseline
- Participants who have a diagnosis of intellectual disability with an intelligence quotient (IQ) score less than 70
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.
The 2 groups in the trial
- EB-1020 (QD XR Capsules) low doseTreatment being tested
Treatment: EB-1020 (Centanafadine) low dose
- EB-1020 (QD XR Capsules) high doseTreatment being tested
Treatment: EB-1020 (Centanafadine) high dose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder
- Fit questions
- Built from NCT07087327, who can take part
- Record updated
- 23 December 2025